RxDoctor Payments Data

Ronald Dulos, MD

Internal Medicine · Riverside, CANPI 1821063710

Payments from drug & device makers

$286in general payments, 2019–2025

Across 14 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$134
  • Lilly USA, LLC$47
  • Dexcom, Inc.$42
  • Novo Nordisk$24
  • GSK$21
  • AstraZeneca$19

What the payments were for

  • Food & beverage$286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott6$134
Lilly USA, LLC2$47
Dexcom, Inc.3$42
Novo Nordisk1$24
GSK1$21
AstraZeneca1$19

How this compares

$286 in reported general payments places this provider in the 55th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$96,256
Medicare patients
235
Services billed
4,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$192,867
JanuviaSitagliptin Phosphate113$132,146
TrulicityDulaglutide64$97,019
OzempicSemaglutide67$86,835
JardianceEmpagliflozin57$65,707
Repatha SureclickEvolocumab49$41,396
FarxigaDapagliflozin Propanediol32$34,570
RybelsusSemaglutide18$30,192
InvokanaCanagliflozin14$22,998
Spiriva HandihalerTiotropium Bromide14$20,230
JanumetSitagliptin Phos/Metformin Hcl20$18,346
MounjaroTirzepatide14$17,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,616
BrilintaTicagrelor17$14,732
Repatha SyringeEvolocumab23$14,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$24$117,02885 claims
Lilly USA, LLCTrulicity, Mounjaro$47$114,88878 claims
AstraZenecaFarxiga, Brilinta$19$49,30249 claims
GSKTrelegy Ellipta, Anoro Ellipta$21$20,85928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →